Hypoactive sexual desire disorder (HSDD) is the most commonly described form of 
female sexual dysfunction. There is currently no pharmacological therapy 
approved to treat HSDD, and therefore, there is an unmet medical need for the 
development of efficacious treatment alternatives. Flibanserin is a novel, 
non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, 
although the application submitted to the U.S. Food and Drug Administration by 
Sprout Pharmaceuticals is only for premenopausal women. Flibanserin works by 
correcting an imbalance of the levels of the neurotransmitters that affect 
sexual desire. More specifically, flibanserin increases dopamine and 
norepinephrine, both responsible for sexual excitement, and decreases serotonin, 
responsible for sexual inhibition. Clinically, flibanserin has exhibited some 
encouraging results in terms of its ability to increase the frequency of 
satisfying sexual events, and the intensity of sexual desire. However, adverse 
events such as dizziness, nausea, fatigue and somnolence, typical of a centrally 
acting drug, are also frequently related to flibanserin treatment.